Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302730 | 0.94 | ALOX5 (0.44) | ESR2ESR1ALOX5SPHK1RARB | |
| SCHEMBL19722295 | 0.85 | SPHK1 (0.52) | ESR1SPHK1RARBCYP3A4 | |
| SCHEMBL19721916 | 0.85 | SPHK1 (0.52) | ESR1SPHK1RARBCYP3A4 | |
| SCHEMBL13302726 | 0.84 | ALOX5 (0.44) | ESR2ESR1ALOX5SPHK1CYP3A4 | |
| SCHEMBL13614363 | 0.82 | DRD2 (0.42) | SPHK1RARBFFAR4 | |
| SCHEMBL12675076 | 0.81 | ESR2 (0.58) | ESR2ESR1ALOX5SPHK1CYP3A4 | |
| SCHEMBL13614328 | 0.81 | DRD2 (0.44) | SPHK1RARBFFAR4 | |
| SCHEMBL13614289 | 0.81 | ESR2 (0.49) | ESR2HSD17B1ESR1CYP3A4CYP2C9 | |
| SCHEMBL12769086 | 0.80 | ESR2 (0.53) | ESR2HSD17B1ESR1CYP3A4CYP2C9 | |
| SCHEMBL21811720 | 0.78 | CNR1 (0.50) | ESR2HSD17B1ESR1HCAR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618690-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7618690-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | CCNE2, CCNE1, CCNL2 | ESR2 206/4885HSD17B1 1972/4885ESR1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.